Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RCUS
#1717
Arcus Biosciences, Inc.
23.1
8
USD
-2.19%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-2.19%
Monthly Change
+2.93%
6 month change
+40.83%
Year Change
+198.33%
Previous Close
23.7
0
Open
23.1
6
Bid
Ask
Low
23.0
6
High
23.2
0
Volume
116
Markets
US Stock Market
Healthcare
RCUS
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
105.84 M
105.89 M
106.43 M
107.97 M
125.35 M
—
Valuation ratios
Enterprise value
1.58 B
699.2 M
727.35 M
1.34 B
2.96 B
5.73 B
Price to earnings ratio
-4.74
-1.86
-2.54
-3.91
-7.24
-15.54
Price to sales ratio
5.2
5.14
3.13
5.86
10.36
24.5
Price to cash flow ratio
-7.89
-2.45
-2.38
-2.95
-5.31
-13.1
Price to book ratio
2.77
0.33
0.37
0.68
4.06
5.43
Enterprise value to EBITDA ratio
-4.46
-1.52
-2.04
-3.43
-7.43
-14.42
Profitability ratios
Return on assets %
-0.08
-0.1
0
-0.14
-0.09
-0.33
Return on equity %
-0.19
-0.21
0
-0.31
-0.17
-0.69
Return on invested capital %
-136.53
-165.99
—
-198.95
-160.28
—
Gross margin %
100
100
100
100
100
400
Operating margin %
-396.15
-435.71
-5
-546.15
-345.45
-1 332.32
EBITDA margin %
-419.23
-450
-6.88
-557.69
-354.55
-1 369.11
Net margin %
-361.54
-400
0
-519.23
-321.21
-1 240.44
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
4.5
5.37
4.5
3.65
4.36
17.88
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.02
0.02
0.14
0.03
0.03
0.22
Solvency ratios
Debt to assets ratio
0.14
0.05
0.1
0.11
0.17
0.44
Debt to equity ratio
0.33
0.11
0.2
0.25
0.31
0.88
Long term debt to total assets ratio
0.04
0.04
0.09
0.1
0.09
0.32
Long term debt to total equity ratio
0.1
0.09
0.18
0.22
0.16
0.65
Per share metrics
Operating cash flow per share
-1.11
-1.34
-1.25
-0.91
-1.12
-4.62
EBIT per share
-1.14
-1.24
-0.08
-1.33
-1.06
-3.71
EBITDA per share
-1.21
-1.28
-0.1
-1.36
-1.09
-3.83
Total debt per share
1.76
0.61
1.02
1.04
1.84
4.52
Cash per share
10.85
10.13
8.55
7.8
9.13
35.62
Net current asset value per share
11.28
10.48
8.88
8.05
9.38
36.78
Tangible book value per share
5.38
5.4
5.15
4.09
5.88
20.52
Working capital per share
8.77
8.53
6.91
5.84
7.23
28.5
Book value per share
5.38
5.4
5.15
4.09
5.88
20.52
News
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data
Arcus Biosciences: Q4 Beat And Casdatifan’s Story So Far (NYSE:RCUS)
Palantir, United Tech among market cap stock movers on Monday
Palantir and AeroVironment among market cap stock movers on Monday
Arcus Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-02-27
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus 2025 presentation: casdatifan data strengthens, I&I pipeline emerges